

CORONARY IMAGING
& PHYSIOLOGY
INNOVATION IN
TRANSCATHETER
INTERVENTIONS



UPO UNIVERSITÀ DEL PIEMONTE ORIENTALE

Paziente con “bridge miocardico”



Domenico D'Amario MD PhD FHFA
Associate Professor of Cardiology
Università del Piemonte Orientale, Novara, ITALY






Background


Myocardial bridge is the most common congenital coronary anomaly in which a segment of the epicardial coronary artery takes a tunneled course under a bridge of myocardium and is squeezed during ventricular systole



The incidence of MB depends on the modality used to identify the tunneled segment:




Myocardial bridge-related ischemia



20 anni, calciatore professionistico italiano, paucisintomatico

Visita d'idoneità




Cortesia Prof. Paolo Zeppilli

20 anni, calciatore professionista, ECG sforzo «falso-positivo»



Cortesia Prof. Daniele Andreini




Cortesia Prof. Domenico D'Amario


87 bpm




111 bpm



140 bpm



140 bpm




6 mesi dopo Debridging a cuore battente



Cortesia Prof. Daniele Andreini



PRE

POST-Debridging




Cortesia Prof. Paolo Zeppilli


15 anni, calciatore, dissociazione AV «isoritmica» e angor



UPO UNIVERSITÀ DEL PIEMONTE ORIENTALE



Coronaria destra che origina dal seno coronarico di Sx con decorso anomalo fra l'aorta e la polmonare intramurale con take off alto





MLA al tratto medio 14.3 mm²

MLA al tratto prossimale con decorso anomalo 5.40 mm²

«Area stenosis» a riposo = 72%



**Valutazione eseguita di base
con infusione di adenosina e.v.
FC 90 bpm**


- **Pd/Pa 0.95**
- **FFR = 0. 76**
- **CFR = 1.2**
- **IMR = 7**



**Valutazione eseguita con
infusione di adenosina e.v.
+ dobutamina e atropina
FC 130 bpm (max)**

- **Pd/Pa 0.83 (aumenta gradiente di base)**
- **FFR = 0. 74**
- **CFR = 1.9**
- **IMR = 9**

Functional assessment of Myocardial Bridging



Functional indices	Diagnostic cut-off	Limitations	Advantages
FFR	≤ 0.80	<ul style="list-style-type: none"> - Underestimation of the hemodynamic significance of MB due to distal pressure overshooting - Pharmacological side effects (adenosine) 	<ul style="list-style-type: none"> - Functional gold standard for CAD - Routinely performed in clinical practice
iFR	$\leq 0,89$	<ul style="list-style-type: none"> - Possible need for inotropic or chronotropic stimulation to unmask the hemodynamic significance of MB 	<ul style="list-style-type: none"> - Diastolic specific-index - No need for pharmacological agents
RFR	$\leq 0,89 ?$	<ul style="list-style-type: none"> - Cut-off values not available for patients with MB - Not routinely performed in clinical practice 	<ul style="list-style-type: none"> - Diastolic specific-index - No need for pharmacological agents
dPR	$\leq 0,89 ?$	<ul style="list-style-type: none"> - Cut-off values not available for patients with MB - Not routinely performed in clinical practice 	<ul style="list-style-type: none"> - Diastolic specific-index - No need for pharmacological agents



UPO UNIVERSITÀ DEL PIEMONTE ORIENTALE






Aims

PRIMARY ENDPOINT

Incidence of **MACE**
(Myocardial infarction, cardiac death and
cardiac hospitalization)
in patients with Myocardial bridge
referred to coronary angiography




SECONDARY ENDPOINTS

Rate of patients with
significant angina
(SAQ < 70)




Impact of **invasive**
intracoronary assessment on
outcomes
(MACE and SAQ)





Study population



Left anterior descending 96,8 %
Circumflex artery 1,5 %
Right coronary artery 0,5 %
Posterior interventricular artery 0,5 %
First diagonal branch 0,5 %
First septal branch 0,2 %

	Number of patients
	444
Male sex (%)	71,8 %
Age (Mean ± SD)	59 ± 11,2
Body mass index (Mean ± SD)	24,6 ± 2,7
	Risk factors
Hypertension (%)	62,8 %
Diabetes, (%)	13,5 %
Dyslipidemia (%)	52,7 %
Former smoker (%)	26,4 %
Active smoker (%)	16,9 %
Stroke history (%)	2,3 %
Previous myocardial infarction (%)	8,3 %
Previous CABG (%)	0,5 %
Previous PCI (%)	14,2 %



MACE	n° of patients at follow-up	n°	(%)
6 months	266	31	11,6 %
12 months	247	16	6,5 %
24 months	193	26	13,5 %

SAQ < 70	n° of patients at follow up	n°	(%)
6 months	266	50	18,8 %
12 months	247	51	20,6 %
24 months	193	42	21,8 %




Personalised Medicine in:






Clinical Presentation: not all bridges are born equal!

Acute (38%) vs Chronic (62%) Coronary Syndromes





Intracoronary imaging




1

To limit underdiagnosis of MB

- Systolic compression of the vessel
- Heterogeneous fusiform band with intermediate-intensity signal, similar to tunica media
- Perivascular "half-moon" surrounding the vessel adventitia
- Sharp borders
- No discontinuity between the fusiform area and the adventitia


Vergallo R, D'Amario D et al under submission



2

To assess MB-associated CAD

Evaluation of atherosclerosis proximal to Myocardial Bridge




3

To guide stenting

PCI with DES in patients with Myocardial Bridge is related to risks:
very late stent thrombosis, stent malapposition, perforation




Full-physiological evaluation



To evaluate the hemodynamic significance both of MB and plaques proximal to MB

To evaluate microvascular Dysfunction






Personalised therapy

n° 72 (17,8%)


PROVOCATIVE
TESTS (ACh)




Tailored
Therapy

Therapy At Discharge	Angio	Angio + ACH	Angio + FFR	P value
Beta Blockers	65,7%	34%	63,6%	<0,001
Calcium Channel Blockers	20,6%	63,8%	20,5%	<0,001


Personalised therapy: incidence of MACE @ 24 months



Personalised therapy: incidence of MACE @ 24 months



Personalised therapy: incidence of MACE @ 24 months





- The early results of the study demonstrate that myocardial bridge is a challenging cause of ischemia in symptomatic patients referred for coronary angiography.

- A remarkable proportion of patients were found to have a myocardial bridge during the occurrence of an acute or chronic coronary syndrome, highlighting that different mechanisms of ischemia may coexist.

- Stratified medical therapy, guided by invasive functional assessment, has a significant impact on cardiovascular outcomes.



UPO UNIVERSITÀ DEL PIEMONTE ORIENTALE








Future perspectives: the RIALTO-PRO

Epicardial disease assessment

1

- NHPR (≤ 0.89)
- cFFR (≤ 0.83)
- FFR (≤ 0.83)



Microvascular disease assessment

2

- IMR (> 25)
- CFR (< 2.0)
- RRR (< 2.0)*

$$*Resistive resistance ratio = \frac{Trm * Pdr}{Thm * Pdh}$$



Vasomotor testing

3

- Ach



Set the new standard for the diagnosis and treatment of patients with MB optimizing the care pathway according to specific endotype

Thank you!

